Active Targeted Therapy Ovarian Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

How It Works

1. Share a Few Details — Enter your cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Targeted Therapy Ovarian Cancer Clinical Trials FAQ

Do I need genetic testing before joining a targeted therapy trial?

Yes, almost always. Targeted therapy trials are designed for patients whose tumors carry a specific mutation, amplification, or fusion — such as EGFR, ALK, ROS1, KRAS, HER2, BRAF, or BRCA. A tissue biopsy or liquid biopsy (ctDNA) is used to identify these alterations. If you haven't had comprehensive molecular profiling, ask your oncologist about next-generation sequencing (NGS) panels.

Are targeted therapy trials available for common mutations like KRAS G12C?

Yes. KRAS G12C inhibitors (sotorasib, adagrasib) are FDA-approved, and next-generation KRAS inhibitors targeting G12C, G12D, and other variants are in active clinical trials. Similar innovation is happening for other historically 'undruggable' mutations. The trial landscape changes quickly — Trialify pulls real-time data from ClinicalTrials.gov so you always see current recruiting studies.

What is the difference between targeted therapy and chemotherapy?

Chemotherapy is cytotoxic — it kills fast-dividing cells (including healthy ones), causing broader side effects like hair loss and nausea. Targeted therapy is designed to block specific molecules that cancer cells need to grow. This precision approach can be more effective for mutation-driven cancers and often has a different side effect profile (more rash, diarrhea, or fatigue than traditional chemo toxicities). Many trials now test combinations of both.

What happens if my cancer develops resistance to a targeted therapy?

Resistance to targeted therapies is common and is one of the most active areas of clinical research. Trials are studying next-generation inhibitors that overcome resistance mechanisms, combination strategies that block escape pathways, and liquid biopsies that detect resistance mutations early. If your cancer has progressed on a targeted agent, ask your oncologist about resistance testing and trials designed for that specific situation.

Targeted Therapy Trials by Cancer Type

• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.
• Melanoma — Melanoma trials are studying next-generation checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and BRAF/MEK targeted combinations — including adjuvant options for resected disease.